BOSTON, LAUSANNE, Switzerland and TAIPEI CITY, Taiwan, March 9,
2022 /PRNewswire/ -- SOPHiA GENETICS (Nasdaq: SOPH)
today announced that SOFIVA GENOMICS, which is one of the largest
genetic testing companies in Taiwan aiming to provide genetic testing to
clinicians, is the first institution in Asia Pacific to adopt SOPHiA GENETICS'
technology to support HRD testing. SOFIVA GENOMICS has been deeply
involved in the field of clinical medicine and cancer monitoring
for many years and found great success while implementing the
solution for advanced HRD (Homologous Recombination Deficiency)
detection using deep learning with the SOPHiA
DDM Platform.
![SOPHiA GENETICS Logo SOPHiA GENETICS Logo](https://mma.prnewswire.com/media/1673202/SOPHiA_GENETICS_Logo.jpg)
SOFIVA GENOMICS has compared the SOPHiA DDM HRD Solution with
alternative solutions on hundreds of ovarian cancer samples and has
concluded that SOPHiA GENETICS offered analysis technology to
simultaneously detect more HRR (Homologous Recombination Repair)
genes, including BRCA 1 and BRCA 2. They evaluated the integrity of
the genome to comprehensively detect the HRD status of patients to
determine whether they are suitable for treatment with precision
therapy.
HRD is a complex biomarker, important for PARP inhibitors that
help identify whether cancer patients may respond better to
specific treatments. It is found in more than half of all cases of
high-grade serous ovarian cancer (HGSOC), which accounts for about
70-80% of all deaths related to ovarian cancer. Its use could
ultimately lead to personalized therapies that benefit the 150,000
patients with ovarian cancer on average per year in Asia Pacific.
While many labs are adopting HRD solutions, having to send
samples out for analysis can get expensive and increase time
between reporting. The SOPHiA DDM Platform offers a unique
technology for detecting HRD with novel deep-learning algorithms.
In addition, the platform helps users enhance their research with
advanced filtering options to discover more actionable insights
from the raw data with more elaborate reporting capabilities.
"Our collaboration with SOPHiA GENETICS will strengthen the
promotion of SOFIVA precision medicine in Taiwan, locally," said Dr. Double
Hong, General Manager of SOFIVA GENOMICS. "SOPHiA
GENETICS offers an in-house HRD solution and allows us to keep our
data ownership. We can together provide the most comprehensive and
accurate HRD testing services in Taiwan."
"It's great to see SOFIVA's positive and rapid response to the
early implementations of our SOPHiA DDM HRD Solution. Our goal has
always been to propel the capabilities of cancer research further.
We anticipate many more clinical institutions will adopt our SOPHiA
DDM platform technology to support HRD testing in the near future
and very much look forward to indirectly supporting their
patients," said Jurgi Camblong, co-founder and CEO of SOPHiA
GENETICS.
About SOFIVA GENOMICS:
SOFIVA GENOMICS is one of the largest genetic testing companies
in Taiwan, accredited by LDTS,
TAF, and certified by CAP and Illumina. Starting from
maternal fetal medicine (MFM), including reproductive, prenatal,
and neonatal genetic testing, SOFIVA GENOMICS has expanded the
scope of its services to precision medicine, including cancer
genetic screening, targeted therapy, and monitoring recurrence or
relapse. SOFIVA GENOMICS provides one-stop genetic testing service
in maternal fetal medicine and precision medicine.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a healthcare technology
company dedicated to establishing the practice of data-driven
medicine as the standard of care and for life sciences research. It
is the creator of the SOPHiA DDM™ Platform, a cloud-based SaaS
platform capable of analyzing data and generating insights from
complex multimodal data sets and different diagnostic modalities.
The SOPHiA DDM™ Platform and related solutions, products and
services are currently used by more than 790 hospital, laboratory,
and biopharma institutions globally. For more information, visit
SOPHiAGENETICS.COM, or connect on Twitter, LinkedIn and Instagram.
Where others see data, we see answers.
SOPHiA GENETICS products are for Research Use Only and not
for use in diagnostic procedures, unless specified otherwise. The
information included in this press release is about products that
may or may not be available in different countries and, if
applicable, may or may not have received approval or market
clearance by a governmental regulatory body for different
indications for use. Please contact
support@sophiagenertics.com to obtain the
appropriate product information for your country of
residence.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute
forward-looking statements. All statements other than statements of
historical facts contained in this press release, including
statements regarding our future results of operations and financial
position, business strategy, products and technology, as well as
plans and objectives of management for future operations, are
forward-looking statements. Forward-looking statements are based on
our management's beliefs and assumptions and on information
currently available to our management. Such statements are subject
to risks and uncertainties, and actual results may differ
materially from those expressed or implied in the forward-looking
statements due to various factors, including those described in our
filings with the U.S. Securities and Exchange Commission. No
assurance can be given that such future results will be achieved.
Such forward-looking statements contained in this document speak
only as of the date of this press release. We expressly disclaim
any obligation or undertaking to update these forward-looking
statements contained in this press release to reflect any change in
our expectations or any change in events, conditions, or
circumstances on which such statements are based, unless required
to do so by applicable law. No representations or warranties
(expressed or implied) are made about the accuracy of any such
forward-looking statements.
Logo -
https://mma.prnewswire.com/media/1673202/SOPHiA_GENETICS_Logo.jpg